US Stock MarketDetailed Quotes

QURE uniQure NV

Watchlist
  • 4.710
  • +0.040+0.86%
Close Apr 18 16:00 ET
  • 4.560
  • -0.150-3.18%
Post 18:21 ET
225.32MMarket Cap-727P/E (TTM)

About uniQure NV Company

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Company Profile

SymbolQURE
Company NameuniQure NV
Listing DateFeb 5, 2014
Issue Price17.00
Founded2012
CEOMr. Matthew C. Kapusta
MarketNASDAQ
Employees480
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
AddressPaasheuvelweg 25a
CityAmsterdam
ProvinceNoord-Holland
CountryNetherlands (the)
Zip Code1105 BP
Phone31-20-240-60-00
Websitehttp://www.uniqure.com

Company Executives

  • Name
  • Position
  • Salary
  • Matthew C. Kapusta
  • Chief Executive Officer and Director
  • 5.63M
  • Dr. Richard Porter, PhD
  • Chief Business and Scientific Officer
  • --
  • Christian Klemt
  • Principal Accounting Officer and Chief Financial Officer; General Manager of uniQure's Amsterdam Site
  • 2.13M
  • Pierre Caloz
  • Chief Operations Officer
  • 2.37M
  • David D. Meek
  • Chairman of the Board
  • 390.68K
  • Dr. Robert Gut, M.D.,PhD
  • Director
  • 350.68K
  • Rachelle S. Jacques
  • Independent Director
  • 353.18K
  • Madhavan Balachandran
  • Independent Director
  • 357.05K
  • Dr. Jeremy P. Springhorn, PhD
  • Independent Director
  • 369.55K
  • Jack L. Kaye
  • Independent Director
  • 368.42K
  • Paula Soteropoulos
  • Independent Director
  • 355.68K
  • Dr. Leonard E. Post, PhD
  • Independent Director
  • 357.05K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg